Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases

Annals of Surgery

Volumn 269, Issue 5, 2019, Pages 917-923

  Chun, Yun Shin ^a   Passot, Guillaume ^a   Yamashita, Suguru ^a   Nusrat, Maliha ^a   Katsonis, Panagiotis ^b   Loree, Jonathan M ^a   Conrad, Claudius ^a   Tzeng, Ching Wei D ^a   Xiao, Lianchun ^a   Aloia, Thomas A ^a   Eng, Cathy ^a   Kopetz, Scott E ^a   Lichtarge, Olivier ^b   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

colorectal liver metastases; RAS; TP53

Indexed keywords

APC PROTEIN; B RAF KINASE; DNA; K RAS PROTEIN; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; GUANOSINE TRIPHOSPHATASE; HRAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PROTEIN P21; TP53 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; GENOMICS; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR-RELATED GENE; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; RISK ASSESSMENT; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; GTP PHOSPHOHYDROLASES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RISK ASSESSMENT; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 85056481796     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002450     Document Type: Article

References (34)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825. discussion 825-7.
3. Passot G, Denbo JW, Yamashita S, et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017;161:332-340.
4. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609-1618.
5. de Rosa N, Rodriguez-Bigas MA, Chang GJ, et al. DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J Clin Oncol. 2016;34:3039-3046.
6. Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol. 2004;11:977-982.
7. Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921-1928.
8. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619-626 [discussion 626-627].
9. Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120:3965-3971.
10. Brudvik KW, Mise Y, Chung MH, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2016;23: 2635-2643.
11. Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54: 1283-1286.
12. Rosty C, Chazal M, Etienne MC, et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer. 2001;95:162-167.
13. Pilat N, Grunberger T, Langle F, et al. Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study. Eur J Surg Oncol. 2015;41:683-689.
14. McMurray HR, Sampson ER, Compitello G, et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature. 2008;453:1112-1116.
15. Parada LF, Land H, Weinberg RA, et al. Cooperation between gene encoding p53 tumour antigen and RAS in cellular transformation. Nature. 1984;312:649-651.
16. Katsonis P, Lichtarge O. A formal perturbation equation between genotype and phenotype determines the evolutionary action of protein-coding variations on fitness. Genome Res. 2014;24:2050-2058.
17. Couinaud C. [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver]. Presse Med. 1954;62:709-712.
18. Edge SB, Byrd DR, Compton CC, et al., American Joint Committee on Cancer. American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
19. Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261-1268.
20. Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33:2753-2762.
21. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
22. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.
23. Neskey DM, Osman AA, Ow TJ, et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 2015;75:1527-1536.
24. Overman MJ, Morris V, Kee B, et al. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016;27:1068-1074.
25. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
26. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120:2316-2324.
27. Bazan V, Agnese V, Corsale S, et al. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol. 2005;16(Suppl 4):iv50-55.
28. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981-989.
29. Garcia-Aguilar J, Chen Z, Smith DD, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-492 [discussion 492-493].
30. Yamashita S, Chun YS, Kopetz SE, et al. APC and PIK3CA mutational cooperativity predicts pathologic response and survival in patients undergoing resection for colorectal liver metastases. Ann Surg. 2017 [Epub ahead of print].
31. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107. doi: 10. 1093/ jnci/dju427.
32. Yamashita S, Brudvik KW, Kopetz SE, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg. 2016. doi: 10. 1097/ SLA. 0000000000002087 [Epub ahead of print].
33. Naccarati A, Polakova V, Parlini B, et al. Mutations and polymorphisms in TP53 gene: an overview on the role in colorectal cancer. Mutagenesis. 2012;27:211-218.
34. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30: 2956-2962.